References
- Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The zidovudine epidemiology study group. J Infect Dis. 1992;166(6):1223–1227. doi:https://doi.org/10.1093/infdis/166.6.1223.
- Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5:1069–1074.
- Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623–683.
- Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with aids and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113(8):1432–1440. doi:https://doi.org/10.1016/j.ophtha.2006.03.021.
- Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS. 1998;12(14):1815–1822. doi:https://doi.org/10.1097/00002030-199814000-00013.
- Holland GN, Vaudaux JD, Shiramizu KM, et al. Characteristics of untreated aids-related cytomegalovirus retinitis. Ii. Findings in the era of highly active antiretroviral therapy (1997 to 2000). Am J Ophthalmol. 2008;145(1):12–22. doi:https://doi.org/10.1016/j.ajo.2007.09.040.
- Leenasirimakul P, Liu Y, Jirawison C, et al. Risk factors for CMV retinitis among individuals with HIV and low cd4 count in northern Thailand: importance of access to healthcare. Br J Ophthalmol. 2016;100(8):1017–1021. doi:https://doi.org/10.1136/bjophthalmol-2016-308556.
- Jabs DA, Van NML, Holland GN, Danis R. Studies of the ocular complications of ARG. Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome after initiating antiretroviral therapy. Am J Ophthalmol. 2017;174:23–32. doi:https://doi.org/10.1016/j.ajo.2016.10.011.
- Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998;338(13):853–860. doi:https://doi.org/10.1056/NEJM199803263381301.
- Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new aids-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(1):231–233. doi:https://doi.org/10.1086/313612.
- Jabs DA, Van Natta ML, Holbrook JT, et al. Longitudinal study of the ocular complications of aids: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007;114(4):780–786. doi:https://doi.org/10.1016/j.ophtha.2006.11.008.
- Ausayakhun S, Watananikorn S, Ittipunkul N, Chaidaroon W, Patikulsila P, Patikulsila D. Epidemiology of the ocular complications of HIV infection in chiang mai. J Med Assoc Thai. 2003;86:399–406.
- Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the aids pandemic. PLoS Med. 2007;4(12):e334. doi:https://doi.org/10.1371/journal.pmed.0040334.
- Pathanapitoon K, Ausayakhun S, Kunavisarut P, et al. Blindness and low vision in a tertiary ophthalmologic center in thailand: the importance of cytomegalovirus retinitis. Retina. 2007;27(5):635–640. doi:https://doi.org/10.1097/01.iae.0000249575.38830.45.
- Ford N, Shubber Z, Saranchuk P, et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: A systematic review. Clin Infect Dis. 2013;57(9):1351–1361. doi:https://doi.org/10.1093/cid/cit494.
- Ausayakhun S, Yuvaves P, Ngamtiphakom S, Prasitsilp J. Treatment of cytomegalovirus retinitis in aids patients with intravitreal ganciclovir. J Med Assoc Thai. 2005;88:S15–20.
- Surachatkumtonekul T, Chokephaibulkit K, Vanprapar N, Pamonvaechavan P. Treatment of cytomegalovirus (CMV) retinitis with intravitreous ganciclovir in HIV-infected children. J Med Assoc Thai. 2008;91:331–337.
- Teoh SC, Ou X, Lim TH. Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. Ophthalmology. 2012;119(3):588–595. doi:https://doi.org/10.1016/j.ophtha.2011.09.004.
- Choopong P, Vivittaworn K, Konlakij D, Thoongsuwan S, Pituksung A, Tesavibul N. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis. BMC Infect Dis. 2016;16:164. doi:https://doi.org/10.1186/s12879-016-1490-6.
- Jabs DA, Ahuja A, Van Natta M, Dunn JP, Yeh S. Studies of the ocular complications of ARG. Comparison of treatment regimens for cytomegalovirus retinitis in patients with aids in the era of highly active antiretroviral therapy. Ophthalmology. 2013;120(6):1262–1270. doi:https://doi.org/10.1016/j.ophtha.2012.11.023.
- Sittivarakul W, Benjhawaleemas T, Aui-Aree N, Jirarattanasopa P, Liabsuetrakul T. Incidence rate and risk factors for contralateral eye involvement among patients with aids and cytomegalovirus retinitis treated with local therapy. Ocul Immunol Inflamm. 2016;24(5):530–536. doi:https://doi.org/10.3109/09273948.2015.1032307.
- Holland GN, Buhles WC Jr., Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV retinopathy. Study group. Arch Ophthalmol. 1989;107(12):1759–1766. doi:https://doi.org/10.1001/archopht.1989.01070020841024.
- Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:https://doi.org/10.1016/S0161-6420(85)34001-0.
- Tun N, Smithuis FM, London N, Drew WL, Heiden D. Mortality in patients with aids-related cytomegalovirus retinitis in myanmar. Clin Infect Dis. 2014;59(11):1650–1651. doi:https://doi.org/10.1093/cid/ciu648.
- Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol. 1989;107(1):75–80. doi:https://doi.org/10.1001/archopht.1989.01070010077031.
- Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche ganciclovir study group. N Engl J Med. 1999;340(14):1063–1070. doi:https://doi.org/10.1056/NEJM199904083401402.
- Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Studies of ocular complications of aids research group in collaboration with the aids clinical trials group. Ophthalmology. 1994;101(7):1250–1261.
- Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994;112(12):1531–1539. doi:https://doi.org/10.1001/archopht.1994.01090240037023.
- The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the foscarnet-ganciclovir cytomegalovirus retinitis trial. The studies of ocular complications of aids (soca) research group in collaboration with the aids clinical trials group (ACTG). Am J Ophthalmol. 1997;124(1):61–70.
- Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol. 1991;109(6):794–799. doi:https://doi.org/10.1001/archopht.1991.01080060058024.
- Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. 2004;111(12):2232–2239. doi:https://doi.org/10.1016/j.ophtha.2004.05.028.
- Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome. Arch Ophthalmol. 2001;119:33–40.